Month: July 2016

Rapid Fecal Calprotectin Level Assessment and the SIBDQ Score Can Accurately Detect Active Mucosal Inflammation in IBD Patients in Clinical Remission: a Prospective Study,

Quantum Blue® fCAL Citation: Voiosu T Benguş A, Dinu R, Voiosu AM, Bălănescu P, Băicuş C, Diculescu M, Voiosu R, Mateescu B.  Rapid Fecal Calprotectin Level Assessment and the SIBDQ Score Can Accurately Detect Active Mucosal Inflammation in IBD Patients in Clinical Remission: a Prospective Study, J Gastrointestin Liver Dis.  2014 Sep;23(3):273-8. doi: 10.15403/jgld.2014.1121.233.thv. Highlight from
Continue Reading

Prospective Evaluation of the Predictive Value of Faecal Calprotectin in Quiescent Crohn’s Disease

BÜHLMANN fCAL® ELISA Citation Naismith, Smith LA, Barry SJ, Munro JI, Laird S, Rankin K, Morris AJ, Winter JW, Gaya DR. A prospective evaluation of the predictive value of faecal calprotectin in quiescent Crohn’s disease. J Crohns Colitis. 2014 Sep;8(9):1022-9. doi: 10.1016/j.crohns.2014.01.029. Highlights from this Publication “The FC result, obtained by non-invasive means, can provide prognostic information
Continue Reading

Estimation of the Possible Economic Effects of Pre-Endoscopic Screening with F-calprotectin, Clinical Biochemistry

BÜHLMANN fCAL® ELISA Citation: Mindemark, M. & Larsson, A. Ruling out IBD: Estimation of the possible economic effects of pre-endoscopic screening with F-calprotectin, Clinical Biochemistry. Clin Biochem. 2012 May;45(7-8):552-5. doi: 10.1016/j.clinbiochem.2011.10.015.

Highlights from this Publication:

“The estimated demand for colonoscopies was reduced by 50% to 67%. This corresponded to a cost avoidance of approximately up toa cost avoidance of approximately up to €2.13 million.”
Continue Reading

Fecal Calprotectin is Equally Sensitive in Crohn’s Disease Affecting the Small Bowel and Colon

BÜHLMANN fCAL® ELISA Citation: Jensen, M.D., Kjeldsen J, Nathan T. Fecal calprotectin is equally sensitive in Crohn’s disease affecting the small bowel and colon. Scand J Gastroenterol. 2011 Jun;46(6):694-700. doi: 10.3109/00365521.2011.560680.

Highlights from this Publication:

“The first study to show that fecal calprotectin is equally sensitive in colonic and small bowel CD.”
Continue Reading

Comparison of Two Immunoassays for Measurement of Faecal Calprotectin in Detection of Inflammatory Bowel Disease: (Pre)-analytical and Diagnostic Performance Characteristics

Quantum Blue®  fCAL Citation Oyaert, M, Trouvé C, Baert F, De Smet D, Langlois M, Vanpoucke H.  Comparison of two immunoassays for measurement of faecal calprotectin in detection of inflammatory bowel disease: (pre)-analytical and diagnostic performance characteristics. Clin Chem Lab Med. 2014 Mar;52(3):391-7. doi: 10.1515/cclm-2013-0699. Highlight from this Publication “The Thermo Fisher device is not reliable for
Continue Reading

Comparative Study of the Quantum Blue Rapid Test and an Established ELISA Method

Quantum Blue®  fCAL Citation Coorevits, L, Baert F , Vanpoucke H.  Faecal calprotectin: comparative study of the Quantum Blue rapid test and an established ELISA method, Clinical chemistry and laboratory medicine: CCLM / FESCC. . 2013 Apr; 51(4):825-31. DOI:10.1515/cclm-2012-0386. “…we may conclude that the POCT can serve as reliable alternative to the time consuming ELISA…” Highlight from
Continue Reading

A New Rapid Test for Fecal Calprotectin Predicts Endoscopic Remission and Postoperative Recurrence in Crohn’s Disease.

Quantum Blue®  fCAL Citation Lobatón, T, , López-García A, Rodríguez-Moranta F, Ruiz A, Rodríguez L, Guardiola J. A new rapid test for fecal calprotectin predicts endoscopic remission and postoperative recurrence in Crohn's disease. Journal of Crohn's & colitis. J Crohns Colitis. 2013 Dec; 7(12):e641-51. doi: 10.1016/j.crohns.2013.05.005. Highlight from this Publication “FC determined by rapid quantitative test
Continue Reading

Validation of a Point-of-Care Desk Top Device to Quantitate Fecal Calprotectin and Distinguish Inflammatory Bowel Disease from Irritable Bowel Syndrome

Quantum Blue®  fCAL Citation Sydora, M. J., Sydora BC, Fedorak RN, 2012, Validation of a point-of-care desk top device to quantitate fecal calprotectin and distinguish inflammatory bowel disease from irritable bowel syndrome, J Crohns Colitis. 2012 Mar;6(2):207-14. doi: 10.1016/j.crohns.2011.08.008. Highlight from this Publication “Quantum Blue Reader® calprotectin levels were available within 30 min and correlated
Continue Reading

Value Fecal Calprotectin in the Evaluation of Patients with Abdominal Discomfort: An Observational Study

BÜHLMANN fCAL® ELISA Citation Manz, M,  Burri E, Rothen C, Tchanguizi N, Niederberger C, Rossi L, Beglinger C, Lehmann FS. Value of fecal calprotectin in the evaluation of patients with abdominal discomfort: an observational study. BMC Gastroenterol. 2012 Jan 10;12:5. doi: 10.1186/1471-230X-12-5. Highlights from this Publication “All together, those results support the concept that fecal calprotectin is
Continue Reading

Monoclonal antibody testing for fecal calprotectin is superior to Polyclonal Testing of Fecal Calprotectin and Lactoferrin to Identify Organic Intestinal Disease in Patients with Adominal Discomfort

BÜHLMANN fCAL® ELISA Citation Burri E, Manz M., Rothen C, Rossi L,Beglinger C, Lehmann S. Monoclonal antibody testing for fecal calprotectin is superior to polyclonal testing of fecal calprotectin and lactoferrin to identify organic intestinal disease in patients with abdominal discomfort. Clinica Chimica Acta. 2013 Feb; 416: 41-47.  doi: 10.1016/j.cca.2012.11.008 Highlights from this Publication “…we demonstrated, that the
Continue Reading